Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE‐deficient mice
Open Access
- 3 May 2013
- journal article
- research article
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 57 (10) , 1718-1728
Abstract
Scope: Xanthohumol (XN), a prenylated antioxidative and anti‐inflammatory chalcone from hops, exhibits positive effects on lipid and glucose metabolism. Based on its favorable biological properties, we investigated whether XN attenuates atherosclerosis in western‐type diet‐fed apolipoprotein‐E‐deficient (ApoE−/−) mice.Methods and results: XN supplementation markedly reduced plasma cholesterol concentrations, decreased atherosclerotic lesion area, and attenuated plasma concentrations of the proinflammatory cytokine monocyte chemoattractant protein 1. Decreased hepatic triglyceride and cholesterol content, activation of AMP‐activated protein kinase, phosphorylation and inactivation of acetyl‐CoA carboxylase, and reduced expression levels of mature sterol regulatory element‐binding protein (SREBP)‐2 and SREBP‐1c mRNA indicate reduced lipogenesis in the liver of XN‐fed ApoE−/− mice. Concomitant induction of hepatic mRNA expression of carnitine palmitoyltransferase‐1a in ApoE−/− mice‐administered XN suggests increased fatty acid beta‐oxidation. Fecal cholesterol concentrations were also markedly increased in XN‐fed ApoE−/− mice compared with mice fed western‐type diet alone.Conclusion: The atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP‐activated protein kinase.Keywords
Funding Information
- Grants F30 SFB LIPOTOX (W1226 DK-MCD, P19186, P22832)
- Austrian Science Fund
This publication has 51 references indexed in Scilit:
- Xanthohumol Prevents Atherosclerosis by Reducing Arterial Cholesterol Content via CETP and Apolipoprotein E in CETP-Transgenic MicePLOS ONE, 2012
- Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BIJournal of Lipid Research, 2012
- Pharmacokinetics of xanthohumol and metabolites in rats after oral and intravenous administrationMolecular Nutrition & Food Research, 2011
- Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout miceBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2011
- AMPK Mediates the Initiation of Kidney Disease Induced by a High-Fat DietJournal of the American Society of Nephrology, 2011
- AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant MiceCell Metabolism, 2011
- Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-κBImmunopharmacology and Immunotoxicology, 2009
- Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasisProceedings of the National Academy of Sciences, 2006
- Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A miceBiochemical and Biophysical Research Communications, 2005
- Regulation of intracellular acetyl-CoA carboxylase by ATP depletors mimics the action of the 5′-AMP-activated protein kinaseBiochemical and Biophysical Research Communications, 1991